Physician profile
Doojin Kim
NPI 1487679858
$40,368.73
in general payments reported to CMS, 2019-2025
39 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $2,400 · 2021: $3,673 · 2022: $3,991 · 2023: $2,964 · 2024: $3,857 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $11K · Travel and Lodging: $1,698 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,485.00 |
| Food and Beverage | $11,310.66 |
| Travel and Lodging | $1,697.80 |
| Education | $144.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $19,471.06 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,526.88 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $2,411.68 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $2,141.21 | 2021-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,868.16 | 2021-2025 | |
| Argenx US, INC. | $1,725.00 | 2022 | |
| Csl Behring | $1,339.29 | 2021-2025 | Kcentra, Andembry, Hizentra |
| Ucb, INC. | $1,325.54 | 2021-2025 | Zilbrysq, Rystiggo |
| Biogen, INC. | $1,296.50 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Emd Serono, INC. | $984.74 | 2019-2025 | Mavenclad, Mavenclad |
| Allergan, INC. | $780.52 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $701.71 | 2022-2025 | Ultomiris, Soliris |
| Pfizer INC. | $636.88 | 2023-2025 | |
| Amgen INC. | $529.43 | 2020-2024 | Aimovig, Uplizna |
| Biohaven Pharmaceuticals, INC. | $371.95 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doojin Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.